| Identification | Back Directory | [Name]
PTK0796 Methanesulfonate | [CAS]
1196800-40-4 | [Synonyms]
OMadacycline (Mesylate)
PTK0796 Methanesulfonate
PTK-0796 Methanesulfonate
PTK 0796 Methanesulfonate
OMadacycline Methanesulfonate
AMadacycline (Methanesulfonate)
OMADACYCLINE METHANESULFONATE; PTK 0796 METHANESULFONATE; PTK-0796 METHANESULFONATE; PTK0796 METHANESULFONATE | [Molecular Formula]
C29H40N4O7.x(CH4O3S) | [MDL Number]
MFCD26142922 | [MOL File]
1196800-40-4.mol | [Molecular Weight]
652.756 |
| Hazard Information | Back Directory | [Description]
Omadacycline, also known as PTK 0796 and Amadacyclin, is a novel first-in-class aminomethylcycline with potent activity against important skin and pneumonia pathogens, including community-acquired methicillin-resistant Staphylococcus aureus (MRSA), β-hemolytic streptococci, penicillin-resistant Streptococcus pneumoniae, Haemophilus influenzae, and Legionella. Omadacycline is active against strains expressing the two main forms of tetracycline resistance (efflux and ribosomal protection). The primary effect of omadacycline is on bacterial protein synthesis, inhibiting protein synthesis with a potency greater than that of tetracycline. The binding site for omadacycline is similar to that for tetracycline. | [Uses]
Omadacycline (PTK 0796) mesylate, a first-in-class orally active aminomethylcycline antibacterial, is a member of the tetracycline class of antibiotics. Omadacycline mesylate acts through the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline mesylate possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as atypical bacteria. Omadacycline mesylate can be used for the research of acute bacterial skin and skin-structure infections, community-acquired pneumonia, and urinary tract infections[1][2][3][4]. | [in vivo]
Omadacycline (0.11-18 mg/kg; a single i.v.) exhibits efficacy against Streptococcus pneumonia, Escherichia coli, and Staphylococcus aureus in mice systemic infection model, with ED50s ranging from 0.30 mg/kg to 3.39 mg/kg[2]. | [IC 50]
Tetracycline | [storage]
4°C, protect from light | [References]
[1] Dur?es F, et, al. Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines. Pharmaceuticals (Basel). 2019 Apr 21;12(2):63. DOI:10.3390/ph12020063
[2] Macone AB, et, al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;58(2):1127-35. DOI:10.1128/AAC.01242-13
[3] Zhanel GG, et, al. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. Drugs. 2020 Feb;80(3):285-313. DOI:10.1007/s40265-020-01257-4
[4] Markham A, et, al. Omadacycline: First Global Approval. Drugs. 2018 Dec;78(18):1931-1937. DOI:10.1007/s40265-018-1015-2 |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
Musechem
|
| Tel: |
+1-800-259-7612 |
| Website: |
www.musechem.com |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|